Oruka Therapeutics, Inc. ORKA Granted (in shares)
Granted (in shares) at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s granted (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s granted (in shares)?
- Oruka Therapeutics, Inc. (ORKA) reported granted (in shares) of $34.31 in Q1 2026.
- How has Oruka Therapeutics, Inc.'s granted (in shares) changed year-over-year?
- Oruka Therapeutics, Inc.'s granted (in shares) increased by 174.9% year-over-year, from $12.48 to $34.31.
- What does granted (in shares) mean?
- The weighted average exercise price of stock options granted to employees and directors during the reporting period. This metric reflects the company's cost of equity-based incentives and the strike price set for new option awards.